Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug

MT Newswires Live

01/21

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said they received a clinical trial approval for SKB445 from the Center for Drug Evaluation of the National Medical Products Administration on Jan. 20, according to a Monday filing with the Hong Kong Stock Exchange.

SKB445, a new antibody-drug conjugate (ADC) drug, shows promise in treating advanced solid tumors, demonstrating efficacy and safety in preclinical studies using OptiDCTM technology, the filing added.

The pharmaceutical company's shares were up by 1% in recent trading.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2505627362"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505627362\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505627362?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-21 10:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505627362","market":"hk","top_or_hot":-1,"title":"Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug","media":"MT Newswires Live","content":"<html><body><p> Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said they received a clinical trial approval for SKB445 from the Center for Drug Evaluation of the National Medical Products Administration on Jan. 20, according to a Monday filing with the Hong Kong Stock Exchange.</p><p>SKB445, a new antibody-drug conjugate (ADC) drug, shows promise in treating advanced solid tumors, demonstrating efficacy and safety in preclinical studies using OptiDCTM technology, the filing added.</p><p>The pharmaceutical company's shares were up by 1% in recent trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-01-21 10:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said they received a clinical trial approval for SKB445 from the Center for Drug Evaluation of the National Medical Products Administration on Jan. 20, according to a Monday filing with the Hong Kong Stock Exchange.</p><p>SKB445, a new antibody-drug conjugate (ADC) drug, shows promise in treating advanced solid tumors, demonstrating efficacy and safety in preclinical studies using OptiDCTM technology, the filing added.</p><p>The pharmaceutical company's shares were up by 1% in recent trading.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4231","symbol_name":"零售房地產信託","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2505627362","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505627362","pubTimestamp":1737427147,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sichuan Kelun-Biotech Biopharmaceutical  said they received a clinical trial approval for SKB445 from the Center for Drug Evaluation of the National Medical Products Administration on Jan. 20, according to a Monday filing with the Hong Kong Stock Exchange.SKB445, a new antibody-drug conjugate  drug, shows promise in treating advanced solid tumors, demonstrating efficacy and safety in preclinical studies using OptiDCTM technology, the filing added.The pharmaceutical company's shares were up by 1% in recent trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托","06990":"科伦博泰生物-B","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","BK1161":"生物科技","ADC":"艾格里房产","BK7095":"多种金属与采矿","ADC.AU":"ACDC Metals Ltd"},"translate_title":"四川科伦生物制药实体瘤药物获得国家药监局批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":0.9,"ADC":1,"ADC.AU":1},"content_text":"Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said they received a clinical trial approval for SKB445 from the Center for Drug Evaluation of the National Medical Products Administration on Jan. 20, according to a Monday filing with the Hong Kong Stock Exchange.SKB445, a new antibody-drug conjugate (ADC) drug, shows promise in treating advanced solid tumors, demonstrating efficacy and safety in preclinical studies using OptiDCTM technology, the filing added.The pharmaceutical company's shares were up by 1% in recent trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}